Peer Support Intervention for Caregivers of Patients Undergoing HSCT
STEPP-Care
1 other identifier
interventional
90
0 countries
N/A
Brief Summary
The main purpose of this study is to determine if a tailored peer support intervention (STEPP-Care) is feasible among caregivers of patients undergoing hematopoietic stem cell transplantation (HSCT).
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P50-P75 for not_applicable
Started Sep 2026
Longer than P75 for not_applicable
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
First Submitted
Initial submission to the registry
April 28, 2026
CompletedFirst Posted
Study publicly available on registry
May 11, 2026
CompletedStudy Start
First participant enrolled
September 30, 2026
ExpectedPrimary Completion
Last participant's last visit for primary outcome
September 30, 2028
Study Completion
Last participant's last visit for all outcomes
September 30, 2031
May 11, 2026
May 1, 2026
2 years
April 28, 2026
May 4, 2026
Conditions
Keywords
Outcome Measures
Primary Outcomes (2)
Intervention Feasibility
Feasibility can be defined as \>/= 60% of STEPP-Care recipients completing 4/6 sessions
up to 10 weeks
Intervention Acceptability
Acceptability can be defined as average STEPP-Care intervention participant ratings \>20 on the Client Satisfaction Questionnaire
up to 10 weeks
Study Arms (2)
STEPP-Care
EXPERIMENTALSTEPP-Care is a phone delivered six session structured peer support intervention.
Usual Care
NO INTERVENTIONRoutine supportive care provided by social workers embedded in the HCT clinical teams will be used as the usual care control condition.
Interventions
STEPP-Care is a phone-delivered six-session structured peer support intervention for caregivers of patients undergoing hematopoietic stem cell transplantation.
Eligibility Criteria
You may qualify if:
- Adult caregivers (≥18 years of age) of patients with hematologic malignancies who are undergoing autologous or allogeneic HSCT at Dana-Farber Cancer Institute.
- Is a relative or friend who is identified by the patient to be their caregiver.
- Ability to speak, read, and respond in English
- Has access to a phone.
You may not qualify if:
- Caregivers with acute or unstable psychiatric conditions or other cognitive conditions that the treating oncologist believes would prohibit informed consent or ability to adhere to study procedures.
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Officials
- PRINCIPAL INVESTIGATOR
Hermioni L. Amonoo, MD, MPP, MPH
Brigham and Women's Hospital
Central Study Contacts
Study Design
- Study Type
- interventional
- Phase
- not applicable
- Allocation
- RANDOMIZED
- Masking
- NONE
- Purpose
- SUPPORTIVE CARE
- Intervention Model
- PARALLEL
- Sponsor Type
- OTHER
- Responsible Party
- PRINCIPAL INVESTIGATOR
- PI Title
- Director, Well-Being and Cancer Research Program
Study Record Dates
First Submitted
April 28, 2026
First Posted
May 11, 2026
Study Start (Estimated)
September 30, 2026
Primary Completion (Estimated)
September 30, 2028
Study Completion (Estimated)
September 30, 2031
Last Updated
May 11, 2026
Record last verified: 2026-05
Data Sharing
- IPD Sharing
- Will not share